DOCK4, a GTPase activator, is disrupted during tumorigenesis

Cell

Volumn 112, Issue 5, 2003, Pages 673-684

  Yajnik, Vijay ^a   Paulding, Charles ^a   Sordella, Raffaella ^a   McClatchey, Andrea I ^a   Saito, Mako ^a   Wahrer, Doke C R ^a   Reynolds, Paul ^a   Bell, Daphne W ^a   Lake, Robert ^a   Van Den Heuvel, Sander ^a   Settleman, Jeff ^a   Haber, Daniel A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GUANOSINE TRIPHOSPHATASE; PROTEIN DOCK4; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ALLELE; ANIMAL CELL; ARTICLE; CAENORHABDITIS ELEGANS; CANCER CELL CULTURE; CARCINOGENESIS; CELL JUNCTION; CONTROLLED STUDY; ENZYME ACTIVATION; GENE DELETION; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; IN VIVO STUDY; MISSENSE MUTATION; MOUSE; MULTIGENE FAMILY; NONHUMAN; OSTEOSARCOMA CELL; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION;

ANIMALIA; CAENORHABDITIS ELEGANS;

EID: 0037423929     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0092-8674(03)00155-7     Document Type: Article

References (59)

1. Albert M.L., Kim J.I., Birge R.B. αvβ5 integrin recruits the CrkII-Dock180-rac1 complex for phagocytosis of apoptotic cells. Nat. Cell Biol. 2:2000;899-905.
2. Asha H., de Ruiter N.D., Wang M.G., Hariharan I.K. The Rap1 GTPase function as a regulator of morphogenesis in vivo. EMBO J. 18:1999;605-615.
3. Boettner B., Govek E.E., Cross J., Van Aelst L. The junctional multidomain protein AF-6 is a binding partner of the Rap1A GTPase and associates with the actin cytoskeletal regulator profilin. Proc. Natl. Acad. Sci. USA. 97:2000;9064-9069.
4. Bos J.L., de Rooij J., Reedquist K.A. Rap1 signalling. adhering to new models Nat. Rev. Mol. Cell Biol. 2:2001;369-377.
5. Brugnera E., Haney L., Grimsley C., Lu M., Walk S.F., Tosello-Trampont A.-C., Macara I.G., Madhanis H., Fink G.R., Ravichandran K.S. Unconventional Rac-GEF activity is mediated through the Dock180-ELMO complex. Nat. Cell Biol. 4:2002;574-579.
6. Call K.M., Glaser T., Ito C.Y., Buckler A.J., Pelletier J., Haber D.A., Rose E.A., Kral A., Yeger H., Lewis W.H.et al. Isolation and characterization of a zinc finger polypeptide gene at the human cromosome 11 Wilms' tumor locus. Cell. 60:1990;509-520.
7. Cavenee W.K., Dryja T.P., Phillips R.A., Benedict W.F., Godbout R., Gallie B.L., Murphree A.L., Strong L.C., White R.L. Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature. 305:1983;779-784.
8. Chen Q., Kimura H., Schubert D. A novel mechanism for the regulation of amyloid precursor protein metabolism. J. Cell Biol. 158:2002;79-89.
9. Christofori G., Semb H. The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. Trends Biochem. Sci. 24:1999;73-76.
10. Clark E.A., Golub T.R., Lander E.S., Hynes R.O. Genomic analysis of metastasis reveals an essential role for RhoC. Nature. 406:2000;532-535.
11. Cote J.F., Vuori K. Identification of an evolutionarily conserved superfamily of DOCK180-related proteins with guanine nucleotide exchange activity. J. Cell Sci. 115:2002;4901-4913.
12. Dryja T.P., Rapaport J.M., Petersen R.A. Molecular detection of deletions involving band q14 of chromosome 13 in retinoblastomas. Proc. Natl. Acad. Sci. USA. 83:1986;7391-7394.
13. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 411:2001;494-498.
14. Fearon E.R. Human cancer syndromes. clues to the origin and nature of cancer Science. 278:1997;1043-1050.
15. Fukui Y., Hashimoto O., Sanui T., Oono T., Koga H., Abe M., Inayoshi A., Noda M., Oike M., Shirai T., Sasazuki T. Haematopoietic cell-specific CDM family protein DOCK2 is essential for lymphocyte migration. Nature. 412:2001;826-831.
16. Gu J., Sumida Y., Sanzen N., Sekiguchi K. Laminin-10/11 and fibronectin differentially regulate integrin-dependent Rho and Rac activation via p130(Cas)-CrkII-DOCK180 pathway. J. Biol. Chem. 276:2001;27090-27097.
17. Guilford P., Hopkins J., Harraway J., McLeod M., McLead N., Harawira P., Taite H., Scoular R., Miller A., Reeve A.E. E-cadherin germline mutations in familial gastric cancer. Nature. 392:1998;402-405.
18. Hajra K.M., Fearon E.R. Cadherin and catenin alterations in human cancer. Genes Chromosomes Cancer. 34:2002;255-268.
19. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 100:2000;57-70.
20. Hariharan I.K., Carthew R.W., Rubin G.M. The Drosphila roughened mutation. activation of a rap homolog disrupts eye development and interferes with cell determination Cell. 67:1991;717-722.
21. Hasegawa H., Kiyokawa E., Tanaka S., Nagashima K., Gotoh N., Shibuya M., Kurata T., Matsuda M. DOCK180, a major CRK-binding protein, alters cell morphology upon translocation to the cell membrane. Mol. Cell. Biol. 16:1996;1770-1776.
22. Hodgson G., Hager J.H., Volik S., Hariono S., Wernick M., Moore D., Nowak N., Albertson D.G., Pinkel D., Collins C.et al. Genome scanning with array CGH delineates regional alterations in mouse islet carcinomas. Nat. Genet. 29:2001;459-464.
23. Jain A.N., Chin K., Borresen-Dale A.L., Erikstein B.K., Eynstein Lonning P., Kaaresen R., Gray J.W. Quantitive analysis of chromosomal CGH in human breast tumors associates copy number abnormalities with p53 status and patient survival. Proc. Natl. Acad. Sci. USA. 98:2001;7952-7957.
24. Jamora C., Fuchs E. Intercellular adhesion, signalling and the cytoskeleton. Nat. Cell Biol. 4:2002;E101-E108.
25. Keely P.J., Westwick J.K., Whitehead I.P., Der C.J., Parise L.V. Cdc42 and Rac1 induce integrin-mediated cell motility and invasiveness through PI(3)K. Nature. 390:1997;632-636.
26. Kamb A., Gruis N.A., Weaver-Feldhaus J., Liu Q., Harshman K., Tavtigian S.V., Stockert E., Day R.S. 3rd, Johnson B.E., Skolnick M.H. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 264:1994;436-440.
27. Kashiwa A., Yoshida H., Lee S., Paladino T., Liu Y., Chen Q., Dargusch R., Schubert D., Kimura H. Isolation and characterization of novel presenilin binding protein. J. Neurochem. 75:2000;109-116.
28. Kitayama H., Sugimoto Y., Matsuzaki T., Ikawa Y., Noda M. A ras-related gene with transformation suppressor activity. Cell. 56:1989;77-84.
29. Kiyokawa E., Hashimoto Y., Kobayashi S., Sugimura H., Kurata T., Matsuda M. Activation of Rac1 by a Crk SH3-binding protein, DOCK180. Genes Dev. 12:1998;3331-3336. a.
30. Kiyokawa E., Hashimoto Y., Kurata T., Sugimura H., Matsuda M. Evidence that DOCK180 up-regulates signals from the CrkII-p130(Cas) complex. J. Biol. Chem. 273:1998;24479-24484. b.
31. Knox A.L., Brown N.H. Rap1 GTPase regulation of adherens junction positioning and cell adhesion. Science. 295:2002;1285-1288.
32. Koike M., Takeuchi S., Yokota J., Park S., Hatta Y., Miller C.W., Tsuruoka N., Koeffler H.P. Frequent loss of heterozygosity in the region of the D7S523 locus in advanced ovarian cancer. Genes Chromosomes Cancer. 19:1997;1-5.
33. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., Puc J., Miliaresis C., Rodgers L., McCombie R.et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 275:1997;1943-1947.
34. Liang H., Guo W., Nagarajan L. Chromosomal mapping and genomic organization of an evolutionarily conserved zinc finger gene ZNF277. Genomics. 66:2000;226-228.
35. Lisitsyn N.A. Representational difference analysis. finding the differences between genomes Trends Genet. 11:1995;303-307.
36. Lisitsyn N., Lisitsyn N., Wigler M. Cloning the differences between two complex genomes. Science. 259:1993;946-951.
37. Lisitsyn N., Wigler M. Representational difference analysis in detection of genetic lesions in cancer. Methods Enzymol. 254:1995;291-304.
38. Lisitsyn N.A., Leach F.S., Vogelstein B., Wigler M.H. Detection of genetic loss in tumors by representational difference analysis. Cold Spring Harb. Symp. Quant. Biol. 59:1994;585-587.
39. McClatchey A.I., Jacks T. Tumor suppressor mutations in mice. the next generation Curr. Opin. Genet. Dev. 8:1998;304-310.
40. McClatchey A.I., Saotome I., Mercer K., Crowley D., Gusella J.F., Bronson R.T., Jacks T. Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev. 12:1998;1121-1133.
41. Meller N., Irani-Tehrani M., Kiosses W.B., Del Pozo M.A., Schwartz M.A. Zizimin1, a novel Cdc42 activator, reveals a new GEF domain for Rho proteins. Nat. Cell Biol. 4:2002;639-647.
42. Nishihara H., Kobayashi S., Hashimoto Y., Ohba F., Mochizuki N., Kurata T., Nagashima K., Matsuda M. Non-adherent cell-specific expression of DOCK2, a member of the human CDM-family proteins. Biochim. Biophys. Acta. 1452:1999;179-187.
43. Nolan K.M., Barrett K., Lu Y., Hu K.Q., Vincent S., Settleman J. Myoblast city, the Drosophila homolog of DOCK180/CED-5, is required in a Rac signaling pathway utilized for multiple developmental processes. Genes Dev. 12:1998;3337-3342.
44. Perego C., Vanoni C., Massari S., Raimondi A., Pola S., Cattaneo M.G., Francolini M., Vicentini L.M., Pietrini G. Invasive behaviour of glioblastoma cell lines is associated with altered organisation of the cadherin-catenin adhesion system. J. Cell Sci. 115:2002;3331-3340.
45. Perl A.K., Wilgenbus P., Dahl U., Semb H., Christofori G. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature. 392:1998;190-193.
46. Reddien P.W., Horvitz H.R. CED-2/CrkII and CED-10/Rac control phagocytosis and cell migration in Caenorhabditis elegans. Nat. Cell Biol. 2:2000;131-136.
47. Reif K., Cyster J. The CDM protein DOCK2 in lymphocyte migration. Trends Cell Biol. 12:2002;368-373.
48. Ren X.D., Schwartz M.A. Determination of GTP loading on Rho. Methods Enzymol. 325:2000;264-272.
49. Schmitz A.A., Govek E.E., Bottner B., Van Aelst L. Rho GTPases. signaling, migration, and invasion Exp. Cell Res. 261:2000;1-12.
50. Schutte M., da Costa L.T., Hahn S.A., Moskaluk C., Hoque A.T., Rozenblum E., Weinstein C.L., Bittner M., Meltzer P.S., Trent J.M.et al. Identification by representational difference analysis of a homozygous deletion in pancreatic carcinoma that lies within the BRCA2 region. Proc. Natl. Acad. Sci. USA. 92:1995;5950-5954.
51. Sekido Y., Pass H.I., Bader S., Mew D.J., Christman M.F., Gazdar A.F., Minna J.D. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res. 55:1995;1227-1231.
52. Shaw R.J., Paez J.G., Curto M., Yaktime A., Pruitt W.M., Saotome I., O'Bryan J.P., Gupta V., Ratner N., Der C.J.et al. The Nf2 tumor supressor, merlin, functions in Rac-dependent signaling. Dev. Cell. 1:2001;63-72.
53. Steck P.A., Pershouse M.A., Jasser S.A., Yung W.K., Lin H., Ligon A.H., Langford L.A., Baumgard M.L., Hattier T., Davis T.et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 15:1997;356-362.
54. Takahashi S., Shan A.L., Ritland S.R., Delacey K.A., Bostwick D.G., Lieber M.M., Thibodeau S.N., Jenkins R.B. Frequent loss of heterozygosity at 7q31.1 in primary prostate cancer is associated with tumor aggressiveness and progression. Cancer Res. 55:1995;4114-4119.
55. Thomas D.M., Hards D.K., Rogers S.D., Ng K.W., Best J.D. Insulin receptor expression in bone. J. Bone Miner. Res. 11:1996;1312-1320.
56. Thomas N.A., Choong D.Y., Jokubaitis V.J., Neville P.J., Campbell I.G. Mutation of the ST7 tumor suppressor gene on 7q31.1 is rare in breast, ovarian and colorectal cancers. Nat. Genet. 29:2001;379-380.
57. Vossler M.R., Yao H., York R.D., Pan M.G., Rim C.S., Stork P.J. cAMP activates MAP kinase and Elk-1 through a B-Raf- and Rap1-dependent pathway. Cell. 89:1997;73-82.
58. Wu Y.C., Horvitz H.R. C. elegans phagocytosis and cell-migration protein CED-5 is similar to human DOCK180. Nature. 392:1998;501-504.
59. Zenklusen J.C., Conti C.J., Green E.D. Mutational and functional analyses reveal that ST7 is a highly conserved tumor-suppressor gene on human chromosome 7q31. Nat. Genet. 27:2001;392-398.